Almirall’s Lebrikizumab Shows Long-Term Efficacy

Almirall (ES:ALM) has released an update.

Almirall has announced that its dermatological treatment, lebrikizumab, has shown sustained efficacy over three years in patients with moderate to severe atopic dermatitis, maintaining clear or almost clear skin in more than 80% of individuals. The treatment, which is a monthly maintenance dose, has also reduced the need for other potent treatments in the majority of patients. These results, consistent with previous safety profiles, will be presented at the EADV Congress in Amsterdam.

For further insights into ES:ALM stock, check out TipRanks’ Stock Analysis page.